ABSTRACT: Background. Queensland, Australia, has the highest rates of cutaneous squamous cell carcinoma (SCC). Perineural invasion (PNI) is associated with reduced local control and survival. Results. Fifty patients (mean age, 60 years) with median follow-up of 50 months were included in this study. A total of 54.8% of known primary tumors had incidental PNI. Ten percent had nodal disease at presentation. MRI neurogram was positive in 95.8%. Recurrence-free survival (RFS) at 5-years was 62%. Five-year disease-specific survival (DSS) and overall survival (OS) were 75% and 64%, respectively. There were no perioperative deaths. Conclusion. This report demonstrates that long-term survival is achievable in patients with clinical PNI from cutaneous SCCHN after surgery and PORT.
INTRODUCTION
Cutaneous squamous cell carcinoma of the head and neck (SCCHN) occurs at epidemic rates in Australia. 1 Perineural invasion (PNI) is defined as the presence of tumor cells in the perineural space of a peripheral nerve and is estimated to occur in <5% of cutaneous SCCHN cases. When PNI is asymptomatic and only detected on histology, it is known as incidental PNI. When there is spread of tumor along the perineural space of a nerve, this is termed clinical PNI or perineural spread (PNS). This may manifest radiologically, histologically, or clinically with progressive symptoms and signs of nerve dysfunction in the distribution of the affected nerve (ie, dysesthesia, facial palsy). The presence of PNS and its extent is best assessed by MRI neurography, preferably using a 3.0 Tesla platform. 2 Clinical PNI is associated with higher rates of local recurrence and reduced overall survival (OR) when compared to incidental PNI. 3, 4 The nerves most commonly affected are the trigeminal (V 1 ophthalmic, V 2 maxillary, and V 3 mandibular divisions) and facial (VII) cranial nerves. PNS along a peripheral nerve is contiguous, and is primarily retrograde (toward the brainstem) yet can be antegrade (toward the skin). Skip lesions (if seen) are likely the result of technical processing artifacts and not tumor emboli. 5, 6 In addition, PNI with concomitant intraneural invasion is seen in the majority of cranial nerve pathological specimens. 6 The natural history of PNS is typically slow retrograde tumor spread toward the brainstem with poor prognosis (ie, central failure).
The American Joint Committee on Cancer (AJCC; 2010 7th edition) classifies all PNI into the skull base as T4 disease. 7 Currently, no consideration is given to the precise zonal extent of PNS, which has been shown to influence patient outcome. 8 Zonal extent of cranial nerve PNS is used at our institution for classification (see Table  1 ). 9 Generally, zone 1 or 2 disease is operable, whereas zone 3 disease is considered not, because of the perceived higher risk of iatrogenic spread of tumor via the cerebrospinal fluid (CSF) during surgery. However, surgery is considered on a case-by-case basis.
The management of clinical PNI varies between institutions yet surgical resection followed by postoperative radiotherapy (PORT) can lead to improved patient outcomes in selected patients. 10 Previously reported outcome data is restricted in its clinical application through the use of varying treatment approaches, 3, 11 and pooling of either incidental PNI and clinical PNI cohorts 12 or different tumor types (ie, squamous cell carcinoma [SCC] and basal cell carcinoma [BCC] ). 4 The purpose of this study was to describe the long-term survival of patients with PNS from cutaneous SCCHN treated with surgery and PORT. Tables 2 and 3) . 7 An "r" notation was applied to the staging if a patient presented with PNS from recurrence of a previously treated primary skin cancer.
MATERIALS AND METHODS
All patients underwent preoperative diagnostic imaging with MRI neurography evaluated by a skull base radiologist, or CT when an MRI was contraindicated. All management plans were discussed in specialized multidisciplinary head and neck and/or skull base tumor boards. Surgical resection was planned with imaging findings and all tumors were resected en bloc with frozen section margin control via a skull base or subcranial approach, as described in Table 4 and in our previous reports. 6, 10, 13 Surgery was of curative intent in all patients. Neck dissection was performed if nodal disease was evident or suspected on preoperative assessment or surgical access to the neck was required to enable reconstruction.
PORT was offered to all eligible patients. Treatment was individualized depending on each patient's suitability and disease extent (skin, nerve, and nodal involvement). In the latter half of the 2000s, prescribed volumes were typically dependent on the zonal extent of disease on imaging and pathology: zone 1 up to ganglion; zone 2 to the prepontine aspect of the nerve; and zone 3 up to the brainstem. 9 Fields encompassed the peripheral branches of involved nerves, and the regional nodes were addressed only if pathologically involved. Bolus was generally considered over the skin corresponding with the nerve distribution. Postoperative concurrent chemoradiotherapy was only used if extracapsular nodal extension was present.
Postoperative follow-up consisted of regular outpatient review (quarterly until 3 years, then biannually until at least 5 years post-treatment) in conjunction with baseline and serial MRI neurography for surveillance (biannually until 3 years, then annually to 5 years). Follow-up was taken from the date of surgery until the date of the last follow-up or date of death. Recurrence was classified as local (further subclassified as peripheral at skin or central at meninges/brain/brainstem), regional (nodal), or distant metastasis. Local recurrences were defined as either an in-field or out-field of radiotherapy (RT). The primary outcomes measured were locoregional control, recurrence-free survival (RFS; any recurrence), disease-specific survival (DSS; death from disease), and overall survival (OS; death from all causes). Variables assessed included age, sex, nodal involvement, nerve(s) involved, single/multiple nerves involved, disease zone, margin status, PORT, salvage versus definitive intent, and tumor differentiation. Because there were only 2 patients with zone 3 disease, zones 2 and 3 were combined for analysis. Crude survival probabilities were estimated and plotted using the Kaplan-Meier technique and analysis was undertaken to assess for significant associations with the variables detailed above. A p value of .05 was deemed statistically significant. Analyses were conducted using SAS software version 9.2 (SAS Institute, Cary, NC).
RESULTS

Patient and primary tumor characteristics
Patient and primary tumor characteristics are described in Table 2 . Mean age at the start of treatment for clinical PNI was 60 years (range, 34-91 years), and the overall male-to-female ratio was approximately 4:1. Median follow-up period after surgery was 50 months (range, 9-151 months).
All tumors with PNS to the skull base are staged as T4, however, as most cases present sometime after the primary has been excised, we assessed the primary cutaneous SCC. Of these, 60% had an obvious primary and the majority was staged as T2 (40%; 20 of 50). Twelve percent of patients presented with PNS having had no cutaneous primary tumor (6 of 50; T0). In 28% of patients, the primary tumor was unassessable (Tx) because of either incomplete/missing pathology reports or cutaneous malignancies treated externally without formal histological diagnosis (ie, cryotherapy, laser, or shave excision through primary care provider), or the exact primary index lesion was uncertain as multiple cutaneous malignancies were present in the region of interest.
The frequencies of all known primary sites are detailed in Table 2 . The cheek was the most common location of a cutaneous primary (20%). In 28% of patients, the location of the primary was unknown yet the approximate location of certain Tx primary tumors was known and therefore included. Of the patients treated with surgery for the primary tumor (34 patients), 12 had involved margins, 8 had close margins, 11 had clear margins, and 3 had unclear margin status. Of the patients with a known primary tumor, 63.3% had incidental PNI reported. From the histopathology reports of primary tumors that included a measurement of involved nerve diameter (n 5 12), the maximal diameter ranged from 0.03 mm to 0.9 mm (median, 0.2 mm).
Assessment
The features of PNS are described in Table 3 . MRI neurogram was performed in 96% of the patients (48 of 50) and was positive for PNS in 95.8% (46 of 48). Two patients were assessed with CT only because of MRI contraindications, and this was positive in 1 patient. All patients with clinically evident PNS of the trigeminal nerve at presentation had disease evident on MRI neurography (43 of 43). The extent of PNS was zone 1 in 32% (16 of 50), zone 2 in 60% (30 of 50), and zone 3 in 4% (2 of 50). Spinal nerve involvement is rare and not currently represented in the zonal classification system. Two patients with great auricular nerve involvement are included in this series. There were 2 patients with negative MRI neurography. One patient, who had a preauricular SCC with incidental PNI previously treated with surgery and PORT, presented with partial facial nerve palsy and no detectable PNS on MRI neurography. The facial nerve branch was 0.5 mm in diameter on histopathology. The second patient presented with a parotid mass and local dysesthesia, and a history of a cheek SCC. Great auricular nerve PNS was detected intraoperatively and confirmed on histopathology (nerve diameter 1 mm), yet the disease was not detectable on MRI neurography.
Ninety-four percent of patients were clinically staged as N0 at presentation. Four percent of patients (2 of 50) were staged N1 and 2% (1 of 50) were staged N2 pathologically. All patients were classified as M0. Eighteen patients (36%) presented with a subcutaneous tumor mass overlying or adjacent to the involved cranial nerve exit foramina. The majority of these were in the V 1 or V 2 distribution, yet masses were also detected under the preauricular skin.
Treatment
All patients underwent en bloc surgical resection of involved nerve(s) with curative intent (for approaches see Table 4 ). 6, 10, 13 Twenty-eight percent of the patients received prior treatment for PNS (surgery and/or RT) and were treated as salvage intent in this series. Five patients (10%) underwent a neck dissection: 3 patients for apparent clinical N1 disease or greater (confirmed pathologically); 1 patient to permit access for reconstruction (N0); and 1 patient because of clinical suspicion (clinical N0, pathological N2b). Thirty-two percent of patients (16 of 50) required an orbital exenteration for V 1 involvement.
There were no perioperative deaths. Surgical complications included: free-flap failure requiring return to operating theater (n 5 1); deep-vein thrombosis (n 5 1); extradural hemorrhage requiring evacuation in the operating theater (n 5 1); CSF leak treated with lumbar drain (n 5 1); and wound infection (n 5 1) treated with washout and antibiotics. In addition, 1 patient sustained an intraoperative myocardial infarction necessitating a change in reconstruction plan (undertaken with local flap instead of free flap). This patient developed perioperative pneumocephalus and a CSF leak with poor neurological recovery requiring rehabilitation, and subsequently died from pneumonia 9 months post-treatment. In addition, 1 patient developed an oroantral fistula after a sublabial approach to V 2 and PORT, and had successful local flap repair.
Clear central nerve margin was obtained in 35 patients (70%) and 5 patients (10%) had close margins (ie, <5 mm clearance). Two patients required a 2-stage operation to clear a nerve margin, whereas 1 patient required a 3-stage operation. Clearance of potential peripheral nerve margin in skin was not pursued because of the risk of disfigurement, and PORT was relied upon for treatment of potential peripheral nerve distribution spread.
The detail of nerves involved is included in Table 3 . V 2 was the most common nerve (42%), followed by V 1 (36%) and VII (36%). The majority of patients had single nerve involvement (68%). Multiple nerve involvement occurred in 32%, with the most common scenario being VII and V 3 co-involvement. The great auricular nerve (C2 spinal nerve) was involved in 2 patients, with disease peripheral to the dorsal root ganglion.
Ninety-four percent of the patients (47 of 50) received PORT with a dose range of 50 to 63 Gray in 25 to 30 fractions daily 5 days/week. Five patients received nodal irradiation for regional nodal disease present on histopathology, and 5 patients had elective nodal irradiation. Two patients who failed previous definitive RT were treated with salvage surgery and not offered further PORT. One patient died of disease after local recurrence 53 months post-treatment, and the other patient remains disease-free 75 months post-treatment. One further patient with zone 1 disease initially not offered PORT because of age (91 years), subsequently developed subcutaneous peripheral recurrence 7 months later, which was treated with salvage surgery and local PORT. This patient remains disease-free 30 months since the last treatment.
Complications after PORT included wound breakdown (n 5 2), radionecrosis (n 5 4; 3 affecting bone and 1 affecting anterior temporal lobe), corneal irritation necessitating orbital exenteration (n 5 2), and visual impairment (n 5 2; radiation microangiopathy) treated conservatively. One patient received chemotherapy (cisplatin) for nodal disease with extracapsular extension.
Outcomes
OS at 5-years was 64% with 14 deaths in this series (see Figure 1) . Ten patients died of their disease, with DSS at 5 years of 75% (see Figure 2) . Mean time to death of disease was 39 months (range, 10-90 months; median, 30 months). The ultimate cause of death was predominantly central failure (12%), none being in the brainstem, with composite peripheral failure in 4% and distant metastasis in 4% (see Table 5 ).
Patterns of recurrence are described in Table 5 . RFS at 5 years was 62% (see Figure 3 ). There were 18 patients with recurrence of disease and 6 patients had a second recurrence. Mean time to any recurrence was 24 months (range, 4-75 months; median, 21 months), with 81% occurring within 4 years and 95% within 5 years posttreatment. Recurrence was significantly associated with worse OS (p 5 .002). Local recurrence was the most common pattern, particularly peripheral in-field (14%). Three patients had central recurrence of disease (2 with simultaneous peripheral and central recurrence), and all died from disease. One patient recurred with regional nodal disease (on the outer edge of the treatment field) and 1 patient recurred with local, regional, and distant disease. Locoregional control at 5 years was 62% (see Figure  4) , and successful surgical salvage of locoregional recurrence was achieved in 33% (6 of 18). Two patients had out-of-field local recurrence on the contralateral side with eventual central failure (1 at 75 months post-treatment, possibly representing a second yet unknown primary). One patient developed out-of-field locoregional recurrence at 20 months post-treatment in the distal branches of V 2 and V 3 , and after salvage surgery remains alive and disease-free at 118 months since the last treatment.
RFS at 5 years by zonal disease extent demonstrated a significant difference when zone 1 (88%) was compared to zones 2 and 3 combined (51%; p 5 .05; see Figure 5 ). DSS at 5 years by zonal disease extent was 93% for zone 1 disease and 73% for zones 2 and 3 combined (p 5 .17). OS at 5 years by zonal disease extent was 75% for zone 1 disease and 63% for zones 2 and 3 combined (p 5 .2). Age, sex, nodal involvement, nerve involved, single versus multiple nerves involved, PORT, salvage versus definitive intent, and tumor differentiation were not associated with recurrence or survival. Margin status did not demonstrate a significant association with recurrence or survival, yet a trend toward significantly better OS was evident when patients with clear/close margins were compared with those with involved margins (p 5 .13; see Figure 6) .
DISCUSSION
This case series details the outcomes of patients with PNS from cutaneous SCCHN treated with surgery and PORT. This treatment approach offers patients a reasonable survival benefit with a limited rate of complications. This is contingent on careful preoperative planning, including appropriate imaging and treatment within a specialized multidisciplinary unit.
The most common location of primary tumor was the cheek, and V 2 disease extending to zone 2 is the most common site and extent of clinical PNI. Almost 40% of known primary tumors did not demonstrate PNI, and this may reflect the inherent difficulties in detecting PNI in an asymptomatic patient.
14 Importantly, the absence of either PNI in a primary tumor or an obvious index lesion does not exclude a patient from having clinical PNI, and can lead to diagnostic delays as the symptoms and signs may be wrongly attributed to Bell's palsy or trigeminal neuralgia. 15 The prognostic significance of nerve diameter in the primary tumor remains unclear, yet it has been proposed that a diameter 0.1 mm is associated with aggressive disease. 16, 17 Standardized pathology reporting to include all high-risk features of cutaneous malignancies is important to permit accurate staging of each primary tumor and to guide appropriate adjuvant treatment. Only 12 of 30 pathology reports of primary tumors included an involved nerve diameter measurement (median, 0.2 mm; range, 0.03-0.9 mm), and robust analysis in this study is therefore not possible.
MRI neurography compliments all aspects of patient management from diagnosis and treatment planning through to follow-up and surveillance. MRI neurography is useful for disease staging with the zonal classification system, which, in turn, guides surgical planning and resection extent and should be offered to all eligible patients. Of note, all patients in this series with V nerve involvement had positive MRI neurography. The 2 cases in this series with MRI-negative disease represented either rare disease (1 patient with great auricular nerve involvement) or early disease (1 patient with partial VII involvement in a previously irradiated parotid bed).
Some centers report imaging-negative PNS at rates of 22% to 47% and this may reflect the use of unfocussed whole-brain MRI or an absence of disease. 3, 18 In our experience, imaging-negative disease in a symptomatic patient is uncommon, as evidenced by 94% of patients in this series being imaging-positive. This is enhanced with the use of 3.0 Tesla MRI with neurography protocol interpreted by a skull base radiologist, with 95.8% being positive. Imaging-positive disease in an asymptomatic patient is rare, and may warrant nerve biopsy before large-scale resection. CT or positron emission tomography/CT imaging is recommended if MRI is contraindicated but lacks sensitivity.
The rate of regional nodal involvement in patients with clinical PNI is estimated at approximately 9% to 16%. 4, 11, 19 The rate of regional nodal disease in this series was low at 10%, and only 2 patients had regional nodal recurrence (1 patients as a first recurrence and 1 patient as a second recurrence). This is consistent with the premise that PNS is likely a function of both tumor biology and proximity to nerve, and is a unique form of metastasis largely independent of lymphatic metastasis. Some centers advocate elective nodal irradiation because of a risk of subclinical disease. 20 Presently, at our institution, nodal irradiation is generally only offered if nodal disease is evident clinically or pathologically. A neck dissection would be undertaken for the same reason, or if required for reconstruction.
Surgical resection for PNS is typically only undertaken with curative intent and the surgical approach to PNS is dictated by the nerve(s) involved, as outlined in Table 4. 13 . This is followed by PORT in all eligible patients. Surgery is offered to patients with zone 1 and zone 2 disease, whereas surgery for zone 3 disease is considered on a caseby-case basis. Resection of bulky zone 3 disease has the potential to cause tumor seeding and dissemination via the CSF and, at our institution, patients with zone 3 disease are generally offered radical or palliative RT.
Complications from surgery were limited and related to the large-scale nature of the surgery required for disease clearance. Importantly, there were no perioperative deaths. RT was also associated with limited treatment effects, however, 2 patients required an orbital exenteration for delayed eye complications (before the use of intensity-modulated radiotherapy). At our institution, it is now largely routine practice to undertake an orbital exenteration for V 1 disease approximately 1 cm beyond the supraorbital notch. This is not only performed for disease clearance, but also because the sequelae from the necessary PORT to the globe are severe. In patients with V 2 and/or V 3 involvement requiring ganglion resection, an attempt is made to preserve corneal sensation by preserving the V 1 component of the ganglion. However, in those patients in whom the whole ganglion was resected to obtain a clear margin, no patient subsequently experienced ophthalmic issues necessitating ongoing management.
A summary of recent outcome data for imaging positive disease is outlined in Table 6 . Previous studies have limited applicability as many have heterogeneous patient cohorts treated with different modalities. 3, 4, 11, 12 This series demonstrates that long-term survival is achievable in patients treated with appropriate surgery and PORT, with almost 65% of patients alive at 5 years. Improved outcomes, including 75% survival from disease at 5 years are evident, compared with previous reports of 58% to 65% in patients with BCC and SCC receiving radiotherapy with limited surgery. 4, 19 Similarly, when compared to another series with a similar patient cohort from the state of Queensland and limited surgery, RFS was 62% in our series compared to 39%. 11 The median time to death of disease in this series was 30 months. One patient died of contralateral spread of disease at 90 months follow-up, 15 months after it was detected. This reflects the often slow spreading nature of PNS, and the inherent ability of tumor to spread to contralateral nerve branches. 21 Local recurrence is the most common mode of treatment failure. Ninety-five percent of all recurrences occurred within 5 years of treatment, reiterating the need for long-term follow-up. At our institution, patients are followed up for at least 5 years.
Recurrence was also noted to be significantly associated with worse OS outcome. This reflects both aggressive tumor biology and the limitations in salvage options after treatment failure, however, up to a third of patients were salvaged with surgery in this series. Of the 3 patients who recurred centrally, none occurred in the brainstem, suggesting that the central spread of disease was controlled by appropriate surgery and targeted PORT. The zonal extent of disease was shown to be significantly associated with risk of recurrence, with RFS at 5 years of 88% in zone 1 and 51% when zones 2 and 3 were combined. These findings demonstrate that improved disease control can be achieved with timely diagnosis and management.
CONCLUSION
This case series demonstrates improved outcomes with relatively low morbidity for patients with cutaneous SCCHN with clinical PNI treated with surgical resection and PORT. Careful surgical candidate selection, preoperative planning with MRI neurography, and management through a specialized multidisciplinary team is recommended. Early intervention is paramount and dependent on a timely diagnosis, and this is expected to improve with advancing imaging technology and increasing clinician and patient awareness of this disease.
